Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 3/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.35 |
| ▸ | BAD | Q92934 | 1/20 | 0.35 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.34 |
| ▸ | TSPO | P30536 | 1/20 | 0.33 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.33 |
| ▸ | CD38 | P28907 | 1/20 | 0.32 |
| ▸ | ICMT | O60725 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | GSK3A | P49840 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7312233 | 0.86 | HTR6 (0.36) | HTR6MCL1NTSR1ICMTGSK3A | |
| SCHEMBL7318525 | 0.86 | NTSR1 (0.38) | HTR6MCL1BADNTSR1TSPO | |
| SCHEMBL7315194 | 0.83 | HTR6 (0.36) | HTR6MCL1NTSR1ICMTGSK3A | |
| SCHEMBL7316939 | 0.82 | OPRM1 (0.36) | HTR6MCL1BADNTSR1ICMT | |
| SCHEMBL7314992 | 0.81 | TSPO (0.46) | HTR6MCL1BADTSPOICMT | |
| SCHEMBL7320265 | 0.80 | ICMT (0.45) | HTR6MCL1BADICMT | |
| SCHEMBL7396434 | 0.74 | MTNR1A (0.36) | CYP19A1MCL1TSPOSERPINE1CHRM1 | |
| SCHEMBL7314014 | 0.74 | HTR6 (0.35) | HTR6MCL1NTSR1ICMTGSK3A | |
| SCHEMBL7306862 | 0.73 | HTR6 (0.35) | HTR6MCL1BADNTSR1ICMT | |
| SCHEMBL7307180 | 0.73 | HTR6 (0.35) | HTR6MCL1NTSR1ICMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010007877-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION | 2001-07-12 | — | — | US | claimed |
| US-20020004198-A1 | Novel anti-infectives | SMITHKLINE BEECHAM CORPORATION | 2002-01-10 | — | — | US | disclosed |
| US-20010007877-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION | 2001-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010007877-A1 | NOVEL ANTI-INFECTIVES | CTSL, MMP8, SERPINB1 | CYP19A1 4833/4885HTR6 4503/4885MCL1 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.